FDA Brief

Warning letters Drugs

FDA warning letter to

Episciences Inc.

High riskIssued Aug 25, 2022Posted Aug 30, 2022Division of Pharmaceutical Quality Operations IV

FDA warns Episciences Inc. that its Boise, Idaho plant made OTC drugs without adequate batch testing, process validation and failure investigations.

What happened

FDA inspected the drug manufacturing facility in Boise, Idaho, from March 7 to 11, 2022, and reviewed the company's March 17, 2022 response to the inspection findings (Form FDA 483, the list of observations given at the end of an inspection). Investigators found that failed test results were cleared without a solid root cause or corrective actions, that manufacturing processes were not properly validated, that most batches were released without full identity, strength and microbiological testing, and that incoming ingredients were not tested for identity. FDA said the missing microbiological testing on each lot was a repeat observation from a 2017 inspection.

What FDA found

  1. FDA said the company's investigations into failed (out-of-specification) test results did not establish a scientifically supported root cause and lacked corrective and preventive actions, and its own procedure let the QA manager release batches that had failed testing.

    21 CFR 211.192
  2. FDA said the company had not properly validated the manufacturing processes for its OTC drug products, and its validation reports left out key quality attributes such as pH, viscosity, appearance and mixing parameters.

    21 CFR 211.100(a) and 211.100(b)
  3. FDA said the company did not test every batch for identity and strength of active ingredients, or for objectionable microorganisms, before release; full testing was done only on batches placed on stability studies, and the microbiological gap was a repeat observation from 2017.

    21 CFR 211.165(a) and 211.165(b)
  4. FDA said the company did not test each incoming component lot to verify its identity and had not qualified its raw material and active ingredient suppliers.

    21 CFR 211.84(d)(1) and 211.84(d)(2)

What FDA wants

FDA tells the company to respond in writing within 15 working days describing what it has done, including a three-year retrospective review of invalidated failed test results, a process validation and testing program, full testing of retained samples of batches still within expiry, and a plan to establish supplier reliability. If corrective actions cannot be finished in that time, the company must give its reasons for delay and a schedule.

Who should pay attention

  • brands and retailers that buy finished OTC drug products from this contract manufacturer
  • companies that accept supplier certificates of analysis instead of testing each incoming ingredient lot
  • quality teams whose procedures let QA release batches with failing test results

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk